Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study

Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study

IntroductionOxaliplatin (OXA) serves as a first-line treatment for digestive system tumors such as colorectal cancer (CRC) and gastric cancer. OXA-induced hypersensitivity reactions (HSRs) may pose life-threatening risks to patients. This study aimed to explore the risk factors and protective factor...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jing Xue, Zhihao Lian, Xiaoyan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Pharmacology
Subjects:	oxaliplatin colorectal cancer hypersensitivity reaction risk factors protective factors
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1624322/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Case report: Tocilizumab for hypersensitivity reaction after oxaliplatin in a patient with NK/T-cell lymphoma
by: Juanyan Liao, et al.
Published: (2025-01-01)

Photodynamic therapy augments oxaliplatin-induced immunogenic cell death in colorectal cancer
by: Xiaobo Wang, et al.
Published: (2023-09-01)

Intra-arterial hepatic chemotherapy in metastatic colorectal cancer: differences between oxaliplatin-naive versus oxaliplatin-pretreated patients
by: E. El Rawadi, et al.
Published: (2025-06-01)

Whitening toothpaste-induced oral mucosal hypersensitivity reaction resembling oral lichenoid reaction: a clinically diagnosed case report
by: Fumin Zheng, et al.
Published: (2025-07-01)

A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions – a retrospective cohort review
by: Nicholas Della Marta, et al.
Published: (2025-01-01)

Oxaliplatin combined with capecitabine therapy and comprehensive nursing in advanced colorectal cancer patients
by: Dan Kuang, et al.
Published: (2025-07-01)

Can Cobalamin prevent Oxaliplatin induced peripheral neuropathy?
by: Naza Shakir Shareef Shekhany, et al.
Published: (2023-06-01)

Salinomycin and oxaliplatin synergistically enhances cytotoxic effect on human colorectal cancer cells in vitro and in vivo
by: Fang Liu, et al.
Published: (2025-04-01)

Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications
by: Angel T. Alvarado, et al.
Published: (2025-08-01)

Oxaliplatin-induced lung fibrosis
by: Shah Arpan, et al.
Published: (2009-01-01)

Evolocumab-induced delayed skin hypersensitivity reaction in a patient with familial hypercholesterolaemia
by: Grzegorz Porebski, et al.
Published: (2024-02-01)

Evaluation of the basophil activation in immediate type hypersensitivity reactions to chemotherapeutic agents
by: Gözde Köycü Buhari, et al.
Published: (2024-02-01)

Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment
by: Khadijeh Falahzadeh, et al.
Published: (2024-09-01)

The Role and Mechanism of Innate Immune Regulation in Overcoming Oxaliplatin Resistance and Enhancing Anti-Tumor Efficacy in Colorectal Cancer
by: Xiaoqing Wang, et al.
Published: (2025-02-01)

IMMEDIATE AND DELAYED HYPERSENSITIVITY REACTIONS TO PROTON PUMP INHIBITORS: A REVIEW ARTICLE
by: Corovic Vahida, et al.
Published: (2025-05-01)

Hypersensitivity Reaction After Administration of Crotalidae Polyvalent Immune Fab (CroFab)
by: Truong L, et al.
Published: (2025-03-01)

Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study
by: Thanutcha Mahathumnuchok, et al.
Published: (2025-08-01)

Investigating the cytotoxic effect of aqueous extract of Peganum harmala on oxaliplatin-resistant HCT116 cell line and evaluating BAX gene expression
by: Zahra Salimizadeh, et al.
Published: (2025-03-01)

Exosomes and their distinct integrins transfer the characteristics of oxaliplatin- and 5-FU-resistant behaviors in colorectal cancer cells
by: Zeynab Vakili-Ghartavol, et al.
Published: (2025-02-01)

Apparent vaccine-thimerosal induced hypersensitivity, myelodysplastic syndrome and pancytopenia
by: Hasan Karsen, et al.
Published: (2007-12-01)

Severe Hypersensitivity Reactions with Oral Manifestations: Case Reports on Stevens-Johnson Syndrome and DRESS Syndrome
by: Sura A. A. Fuoad Al-Bayati
Published: (2024-12-01)

Hypersensitivity reactions to iodinated contrast media: potential mechanisms and clinical management
by: Xia Zhong, et al.
Published: (2025-05-01)

DIRAS1 Drives Oxaliplatin Resistance in Colorectal Cancer via PHB1-Mediated Mitochondrial Homeostasis
by: Min Long, et al.
Published: (2025-07-01)

Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis
by: Shaoqing Fan, et al.
Published: (2025-04-01)

Hypersensitivity reaction to etoposide. A case report
by: M. Mullera Martí, et al.
Published: (2014-05-01)

Astragalus-Zedoary Inhibits Epithelial–Mesenchymal Transition in Colorectal Cancer MC38 Cell Xenograft Mice to Promote Oxaliplatin Attenuation and Sensitization
by: Lei Liu, et al.
Published: (2025-01-01)

Dental Erosion Prevalence and Risk Factor in Hypersensitive Patients
by: Abdul S. T. Ali, et al.
Published: (2024-08-01)

Stability study of oxaliplatin and doxorubicin for intraperitoneal administration with hyperthermia
by: V. Escudero-Ortiz, et al.
Published: (2014-05-01)

Isoalantolactone induces the apoptosis of oxaliplatin-resistant human colorectal cancer cells mediated by ROS generation and activation of JNK and p38 MAPK
by: Seung-On Lee, et al.
Published: (2025-04-01)

Oxaliplatin-related neuropathy in Indian patients – no difference between generic and original molecules
by: Bhawna Sirohi, et al.
Published: (2016-01-01)

A placebo-controlled study of the doses and efficacy of Lentinula edodes mycelia for oxaliplatin-induced peripheral neuropathy in colorectal cancer
by: Shogen Boku, et al.
Published: (2025-08-01)

Oxaliplatin-induced neuropathic pain in cancer: animal models and related research progress
by: Yuxin Jiang, et al.
Published: (2025-05-01)

Excipients in pharmaceuticals: mechanisms of hypersensitivity and the role of global pharmacovigilance
by: Ruba Malkawi, et al.
Published: (2025-07-01)

Some aspects of liposomal oxaliplatin formulations
by: A. V. Stadnichenko, et al.
Published: (2015-02-01)

AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer
by: Zhiwen Fu, et al.
Published: (2024-12-01)

Clinical Presentations and Characteristics of NSAIDs Hypersensitivity in a Tertiary Care Hospital in Indonesia: A Case Series
by: Nurmesa A, et al.
Published: (2025-01-01)

Risk factor of severe diarrhea and enterocolitis induced by CAPOX: a retrospective multicenter study
by: A. Teixeira, et al.
Published: (2024-12-01)

Comparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer
by: Fei-Yu Wang, et al.
Published: (2025-03-01)

Effect of Melatonin on Oxaliplatin Induced Neuropathy in Patients Receiving Folfox Chemotherapy Regimens for Stage II–IV Colorectal Cancer: A Randomized, Placebo Controlled, Double Blind Trial
by: Raziyeh Kheshti, et al.
Published: (2025-05-01)

Therapeutic effect of Chelidonium majus hydro-alcoholic extract alone and in combination with oxaliplatin on ovarian cancer cell line
by: Zahra Hashempour, et al.
Published: (2025-07-01)